Health related quality of life among postmenopausal woman with hormone responsive HER2− breast cancer in Indonesia

Abstract

Objectives Breast cancer (BC) in women could decrease health-related quality of life (HRQoL). HRQoL becomes important to be assessed to design a relevant treatment that could improve patient outcomes. Furthermore, assessing HRQoL by measuring health state utilities becomes pivotal for health economic evaluation. This study aimed to describe the HRQoL of postmenopausal women with hormone responsive (HR+) HER2− BC using the EQ5D5L instrument in Indonesia. Methods A cross-sectional study was conducted among 126 patients in Dr. Sardjito Hospital in Indonesia. The HRQoL was assessed by interviewing BC patients using the EQ5D5L questionnaire, and the utility index was calculated using the Indonesian value set. Information regarding clinical characteristic and socio-demographic were gained from patient medical records. One-way ANOVA and post-hoc Scheffe’s test was performed to compare the utility score within the health state. Results Of the 126 patients, a mean ± SD for the age of 59.2 ± 6.1 years. The major problems of patients were pain/discomfort (75.4%) followed by anxiety/depression (54.8%). The mean (SD) of EQ5D VAS was 76.64 (14.91). Mean (SD) of utility score was 0.87 (0.10), 0.77 (0.19) and 0.58 (0.44) for free metastasis (FM), locoregional metastasis (LM) and distant metastasis (DM), respectively. Poor QoL was observed at DM health state (p<0.05). Conclusions HRQoL of postmenopausal women with HR+ HER2− BC was low. The major reported problems were pain/discomfort and anxiety/depression.

The impact of age on health utility values for older women with early-stage breast cancer: a systematic review and meta-regression

“…The HSUVs were distributed across three health states: stable ( n = 33), progressed disease ( n = 10), and advanced disease ( n = 7). The EQ-5D-3L ( n = 43) [ 37 – 46 , 48 ] instrument was used more often than the EQ-5D-5L instrument ( n = 7) [ 47 , 49 ]. Six different valuation tariffs were applied across the sample, including the UK 3L ( n = 28) [ 37 – 39 , 41 , 42 , 46 , 48 ], US 3L ( n = 2) [ 40 ], Canada 3L ( n = 4) [ 45 ], Korea 3L ( n = 5) [ 44 ], China 3L ( n = 4) [ 43 ], China 5L ( n = 4) [ 47 ], and Indonesian 5L ( n = 3) [ 49 ] tariffs (Fig.…”

“…Fifty HSUVs were identified from the 13 studies [ 37 – 49 ] (Table 2 ). The HSUVs were distributed across three health states: stable ( n = 33), progressed disease ( n = 10), and advanced disease ( n = 7).…”

“…Across the whole sample, these HSUV values were estimated from patients with a mean age between 44 and 75 years. One study defined their sample as 'postmenopausal women [ 49 ], and the remaining studies (92%) had a sample of women whose mean age was over 45 years.…”

“…(2020) [ 47 ] China 08/2017–05/20 Questionnaire Patients' own health EQ-5D-5L China 51.37 446 Etikasari , et al . (2021) [ 49 ] Indonesia 01/2019–08/2019 Questionnaire Patients' own health EQ-5D-5L Indonesian 59.2 126 * Respondent age in Freedman [ 40 ] was 45–64 years (57%); ** Respondent age in Tanaka [ 46 ] for usual care: 53.4 years, pharmacist care: 57.6 years

Fig. 2 Health state utility values by health state and valuation tariff

…”

Quality of Life of Cancer Patients during Chemotherapy in Indonesia: A Comparison of EORTC QLQ-C30 and EQ-5D-5L, Based on Patients’ Characteristics

“…Most investigations have found that cancer patients' HRQoL is deteriorating during cancer treatments. Tis condition highlights the need for evidence-based education and psychological interventions to improve their condition during the treatment [7][8][9][10][11]. Valid and reliable questionnaires about cancer patients' HRQoL are available and have been adapted into various languages worldwide, including Indonesia.…”